Enhertu breast cancer drug gets broader U.S. approval


Date: 26.01.2021

Enhertu is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received two or more prior anti-HER2 breast cancer treatments.

AstraZeneca and Daiichi Sankyo’s breast cancer drug has been approved as a treatment for a certain type of advanced gastric cancer in the United States, the British drugmaker said on Monday.

Drugmakers are using biomarker-driven drugs to treat patients with rare tumours. AstraZeneca made a $7-billion bet on the treatment, Enhertu, when it partnered with Daiichi in 2019 in a direct challenge to Roche.

The treatment has now been approved as a therapy for patients with previously treated HER2-positive advanced gastric cancer, AstraZeneca said, adding it now owes $115 million in milestones to Japan’s Daiichi for the latest indication.

“Today’s approval of Enhertu represents the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer,” Dave Fredrickson, executive vice-president of AstraZeneca’s oncology business unit said.

Source: Reuters

Views: 15

Leave a request

Select option
Thank you, application submitted.